Multicentre, prospective, randomised open-label blinded endpoint (PROBE) phase III study in stroke thrombolysis patients to compare tenecteplase and alteplase for an outcome of less disability at 3 months.
Latest Information Update: 27 Aug 2024
At a glance
- Drugs Tenecteplase (Primary) ; Alteplase
- Indications Embolism and thrombosis; Stroke
- Focus Therapeutic Use
- Acronyms TASTE
- 01 Aug 2024 Status changed from recruiting to discontinued as per results presented in in the Lancet Neurology.
- 01 Aug 2024 Results assessing the non-inferiority of tenecteplase versus alteplase on clinical outcomes in patients selected by use of perfusion imaging presented in the Lancet Neurology
- 02 Mar 2023 This trial has been completed in Belgium, according to European Clinical Trials Database record.